FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Vashington, I	D.C. 20549
---------------	------------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per respon	nse: 0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Nuss John					2. Issuer Name and Ticker or Trading Symbol Ventyx Biosciences, Inc. [ VTYX ]											5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner						
(Last)	,	,	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 03/28/2024										X Office below	(give title	TIFIC	Other (specify below)			
C/O VENTYX BIOSCIENCES, INC. 12790 EL CAMINO REAL, SUITE 200					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)										Individual or Joint/Group Filing (Check Applicable Line)						
(Street)	EGO C	A !	92130		-												filed by Mo		orting Person	- 1		
(City)	(S	tate)	(Zip)		Ru	Rule 10b5-1(c) Transaction Indication																
												ction was r					on or writter	plan t	hat is intende	d to		
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																					
1. Title of Security (Instr. 3)  2. Trans Date (Month.					ar) E	2A. Deemed Execution Date, if any (Month/Day/Year		·,	Code (Instr.					Securiti Benefic	5. Amount of Securities Beneficially Owned Following		n: Direct or Indirect ostr. 4)	7. Nature of Indirect Beneficial Ownership				
								-	Code	v	Amount		(A) or (D)	Price	Transac (Instr. 3	tion(s)			(Instr. 4)			
Common Stock				03/2	8/2024					M		4,53	1	A	<b>\$0</b> <sup>(1)</sup>	26	5,649 I		D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Dat if any (Month/Day/Ye	Date,	Code (In				6. Date Exercisal Expiration Date (Month/Day/Year				Amo Secu Unde Deriv	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	s B Ily	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exe	te ercisable		xpiration ate	Title		Amount or Number of Shares							
Restricted Stock	(1)	03/28/2024			M			4,531		(2)		(2)	Com Sto	nmon	4,531	\$0	13,59	4	D			

## **Explanation of Responses:**

- 1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Ventyx Biosciences, Inc. common stock.
- 2. Twenty-five percent (25%) of the restricted stock units subject to the RSU Award shall vest on the one (1) year anniversary of the RSU Vesting Commencement Date (as defined below), and twenty-five percent (25%) of the total restricted stock units subject to the RSU Award shall vest each year thereafter on each annual anniversary of the RSU Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the reporting person continuing to be a Service Provider (as defined in the Plan) through each such date. The RSU Vesting Commencement Date shall mean March 28, 2023.

/s/ Christopher Krueger, as Attorney-in-Fact \*\* Signature of Reporting Person

03/29/2024 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.